Statin use in adults at high risk of cardiovascular disease mortality: cross-sectional analysis of baseline data from The Irish Longitudinal Study on Ageing (TILDA) by Murphy, Catriona et al.
Statin use in adults at high risk of
cardiovascular disease mortality:
cross-sectional analysis of baseline data
from The Irish Longitudinal Study
on Ageing (TILDA)
Catriona Murphy,1 Kathleen Bennett,2 Tom Fahey,3 Emer Shelley,4 Ian Graham,5
Rose Anne Kenny1
To cite: Murphy C,
Bennett K, Fahey T, et al.
Statin use in adults at high
risk of cardiovascular disease
mortality: cross-sectional
analysis of baseline data from
The Irish Longitudinal Study
on Ageing (TILDA). BMJ
Open 2015;5:e008017.
doi:10.1136/bmjopen-2015-
008017
▸ Prepublication histor for
this paper is available online.
To view these files please
visit the journal online
(http://dx.doi.org/10.1136/
bmjopen-2015-008017).
Received 19 February 2015
Revised 29 May 2015
Accepted 25 June 2015
For numbered affiliations see
end of article.
Correspondence to
Dr Catriona Murphy;
Catriona.murphy@tcd.ie
ABSTRACT
Objectives: This study aims to examine the extent to
which statins are used by adults at high risk of
cardiovascular disease (CVD) compared to European
clinical guidelines. The high-risk groups examined are
those with (1) known CVD, (2) known diabetes and (3)
a high or very high risk (≥5%) of CVD mortality based
on Systematic COronary Risk Evaluation (SCORE).
Design: This study is cross-sectional in design using
data from the first wave (2009–2011) of The Irish
Longitudinal Study on Ageing (TILDA).
Setting and participants: The sample (n=3372) is
representative of community living adults aged
50–64 years in Ireland.
Results: Statins were used by 68.6% (95% CI 61.5%
to 75.8%) of those with known CVD, 57.4% (95% CI
49.1% to 65.7%) of those with known diabetes and by
19.7% (95% CI 13.0% to 26.3%) of adults with a
SCORE risk ≥5%. Over a third (38.5%, 95% CI 31.0%
to 46.0%) of those with known CVD, 46.8% (95% CI
38.4% to 55.1%) of those with known diabetes and
85.2% (95% CI 79.3% to 91.1%) of those with a
SCORE risk ≥5% were at or above the low-density
lipoprotein cholesterol (LDL-C) target of 2.5 mmol/L
specified in the 2007 European guidelines.
Conclusions: Despite strong evidence and clinical
guidelines recommending the use of statins for
secondary prevention, a gap exists between guidelines
and practice in this cohort. It is also of concern that a
low proportion of adults with a SCORE risk ≥5% were
taking statins. A policy response that strengthens
secondary prevention, and improves risk assessment
and shared decision-making in the primary prevention
of CVD is required.
INTRODUCTION
Cardiovascular disease (CVD) is the leading
cause of mortality globally1 and accounts for
about a third of all deaths in Ireland.2
Dyslipidaemia, especially hypercholesterolaemia,
plays a major role in the development of CVD.
Evidence from randomised controlled
trials has estimated that a 1 mmol/L individ-
ual level reduction in low-density lipoprotein
cholesterol (LDL-C) is associated with a
20–25% reduction in CVD mortality and
non-fatal myocardial infarction, regardless
of an individual’s initial lipid proﬁle.3 4
Lipid-lowering drugs include statins, ﬁbrates,
bile acid sequestrants, nicotinic acid and
selective cholesterol absorption inhibitors.
Statins not only reduce LDL-C but halt pro-
gression, and may contribute to regression of
coronary atherosclerosis.5 6 Statins are, there-
fore, used as the drugs of ﬁrst choice in
patients with hypercholesterolaemia3 and for
lowering LDL-C in the vast majority of indivi-
duals with a high risk of CVD and associated
mortality.7 The role of statins in the second-
ary prevention of CVD morbidity and mortal-
ity is well established, resulting in clinical
guidelines that recommend statin prescrip-
tion to all adults with clinical evidence of
Strengths and limitations of this study
▪ This is the first study to examine the use of
statins in community living adults (50–64 years)
at high risk of cardiovascular disease (CVD) in
Ireland.
▪ Study strengths include the large nationally rep-
resentative sample, structured collection of inter-
view data and standardised protocols for
objective health measures.
▪ Potential limitations include the reliance on self-
reports of doctors’ diagnosis of CVD and dia-
betes, and the absence of information on those
that declined or discontinued statin treatment.
▪ Despite strong evidence on the benefits of statin
use for prevention of CVD, this study reveals a
gap between guidelines and practice in this
group.
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CVD.8–11 Statins also play a role in the primary preven-
tion of CVD for adults at high risk of CVD. This includes
those with diabetes,8–10 those with familial hypercholes-
terolaemia12 and those with a high or very high (≥5%)
Systematic COronary Risk Evaluation (SCORE) in
combination with deﬁned LDL-C threshold levels.3
European guidelines on CVD prevention in clinical prac-
tice, including the management of dyslipidaemia, were
published in 200712 and updated in 2012.3
This study aims to examine the extent to which statins
are used by adults (50–64 years) at high risk of CVD
morbidity and mortality in Ireland compared to
European clinical guidelines. The high-risk groups
examined include those with: (1) known CVD, (b)
known diabetes and (3) a high or very high risk (≥5%)
of CVD mortality based on SCORE.13
METHODS
Design and data collection
The study uses cross-sectional data from a nationally rep-
resentative sample of community living adults aged
50 years and older in Ireland. The sample was recruited
based on a national directory of residential addresses
using the RANSAM system.14 The data were collected as
part of the ﬁrst wave of the Irish Longitudinal Study on
Ageing (TILDA). All participants provided written
informed consent.
Data were collected between October 2009 and July
2011. Participants took part in a face-to-face computer-
assisted personal interview in their home followed by a
health assessment in a designated centre or in their
home. Further details are available elsewhere on the
health assessment element of this study.15
Measurements
Participants were asked “Has a doctor ever told you that
you have any of the following conditions?” CVD (angina,
myocardial infarction, coronary artery bypass surgery,
stroke or transient ischaemic attack (TIA)) and diabetes
(types I and II) classiﬁcation were based on participant
responses to this question or a self-report of having
undergone an angioplasty or stent insertion procedure.
Information on current smoking status was collected
during the interview.
Current medication use, including statin therapy, was
recorded by the interviewer during the home-based
interview and cross-checked using medication labels.
Good agreement has been demonstrated in this cohort
between self-report and pharmacy dispensing records
for lipid-modifying agents (κ=0.73, 95% CI 0.69 to
0.77).16 Medication was classiﬁed according to the WHO
Anatomical Therapeutic Chemical classiﬁcation system.
All 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)-
reductase inhibitors (statins) were coded as C10AA, and
those in combination with other lipid-modifying agents
and with other combinations, coded as C10B, were com-
bined to create a single statin variable.
Blood pressure was measured during the health assess-
ment by a nurse according to a standard protocol.
A digital automated oscillometric blood pressure
monitor (Omron M10-IT, Omron Inc, Kyoto, Japan) was
used to measure blood pressure while the respondent
was seated comfortably in an upright position after a
period of rest. Blood pressure was recorded twice while
seated with a timed interval of 1 min between readings.
The mean systolic blood pressure obtained from these
two measurements was used in SCORE.
Non-fasting venous blood was drawn to estimate total
cholesterol, high-density lipoprotein cholesterol
(HDL-C) and triglycerides. LDL-C was estimated based
on the Friedewald equation.17 Total cholesterol and
LDL-C were grouped according to targets set in the
200712 guidelines and threshold categories for drug
intervention in the 20123 guidelines.
High-risk groups
SCORE estimates the 10-year risk of ﬁrst fatal athero-
sclerotic event in those aged 40–64 years.13 The youngest
TILDA participants were 50 years old; therefore, this
study is limited to those aged 50–64 years. SCORE was
developed to provide a risk scoring system for use in the
clinical management of cardiovascular risk in partici-
pants without known CVD in European clinical practice.
It includes the following risk factors: age, sex, systolic
blood pressure, total cholesterol and smoking status.
Risk equations have been developed for ‘low risk’ and
‘high risk’ countries3 based on cut-off points for CVD
and diabetes mortality in men and women in 2008.
Ireland was classiﬁed as ‘low risk’; therefore, the corre-
sponding risk equations were applied to the TILDA data
in this study.
Those with known CVD, diabetes mellitus and familial
hypercholesterolaemia are considered to be at high
risk.3 12 Those with familial hypercholesterolaemia
(LDL-C >6 mmol/L, n=13) were not analysed in this
study due to the small number found. The remainder of
the sample was grouped into four categories according
to the SCORE protocol: low risk (<1%), moderate risk
(≥1% and <5%), high risk (≥5% and <10%) and very
high risk (≥10%) of CVD mortality. The high-risk and
very high risk groups were collapsed into a single
SCORE ≥5% high-risk group.
Covariates
Demographic covariates included age, sex and highest
educational attainment (primary, secondary and ter-
tiary). Access to primary healthcare was assessed using
entitlement to a means tested medical card which pro-
vides free access to general practitioner (GP) care and
heavily subsidised prescribed medicines. Frequency of
GP visits was recorded as the number of visits to the GP
in the previous 12 months.
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Statistical analysis
We calculated the prevalence and 95% CIs for CVD, dia-
betes, and high or very high SCORE risk in the age
group of 50–64 years. Respondent groups were com-
pared using χ2 tests for categorical variables and t tests
for continuous variables. Generalised linear models with
binomial distribution, log link function and robust
standard errors were used to determine the association
between medical card status and statin utilisation in the
three groups at high risk of CVD mortality, adjusting for
age, sex, level of education and frequency of GP visits.
Unadjusted and adjusted risk ratios (RRs) and 95% CIs
are presented.
Estimates of the absolute number of individuals subop-
timally treated with statins in the high-risk groups were
calculated based on the 2012 guidelines3 and using
population data from Census 2011.18 Survey weights
based on age, sex and educational attainment were
applied to reduce non-response bias to the interview
stage of the survey. Additional weights based on health
and demographic factors were applied to increase the
representativeness of the sample used in the analysis.
Statistical signiﬁcance was set at p<0.05. The statistical
software Stata/MP V.12.1 was used to conduct the
analyses.
RESULTS
The overall household response rate was 62%. In total,
8175 respondents completed the home-based interview,
57.1% (n=4668) of these respondents were aged
50–64 years (ﬁgure 1). Of these, 75.3% (n=3517) com-
pleted a health assessment (91.6% in a health assess-
ment centre, 8.4% in the respondent’s home). Owing to
small numbers, the high-risk group with LDL-C
>6 mmol/L (n=13) were excluded from the analysis as
were those with missing data (n=132). The ﬁnal sample
size for analysis consisted of 3372 individuals with full
risk factor data available.
Characteristics of the sample by sex are provided in
table 1. The mean age of the sample was 56.7 (SD=4.2)
years and 45% were men. Almost one-ﬁfth were current
smokers (18.3%), and smoking was equally distributed
between men and women. Total cholesterol, LDL-C and
HDL-C levels were higher in women compared to men.
In contrast, triglycerides, systolic and diastolic blood
pressure levels were higher in men compared to women.
High-risk groups
Three high-risk groups for CVD mortality were identi-
ﬁed: those with known CVD, those with known diabetes
and those at high or very high (≥5%) SCORE risk. Of
those aged 50–64 years, 4.9% (95% CI 4.1% to 5.6%)
(n=166) had known CVD, including 23 with diabetes.
A further 4.2% (95% CI 3.5% to 4.8%) (n=141) had
self-reported diabetes without CVD (ﬁgure 1).
SCORE 10-year risk of CVD mortality was estimated in
those without evidence of CVD or diabetes (n=3065).
The majority were classiﬁed as low risk (40.9%, 95% CI
Figure 1 Flow chart of the number of participants included in the analysis (CVD, cardiovascular disease; LDL-C, low-density
lipoprotein cholesterol; SCORE, Systematic COronary Risk Evaluation; TILDA, The Irish Longitudinal Study on Ageing).
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39.2% to 42.6%) (n=1255) or moderate risk (54.4%,
95% CI 52.6% to 56.1%) (n=1668), with a smaller pro-
portion at high risk (4.0%, 95% CI 3.3% to 4.7%)
(n=124) or very high risk (0.6%, 95% CI 0.3% to 0.8%)
(n=18). The pattern of risk differed between men and
women. The low-risk group was comprised mostly of
women, whereas men were in the majority in the moder-
ate, high and very high risk groups. When the high-
risk and very high risk groups were combined, 4.6%
(95% CI 3.8% to 5.3%) (n=142) of those classiﬁed
using SCORE had a ≥5% 10-year risk of CVD mortality
(ﬁgure 1).
Statin use in the groups at high risk
LDL-C levels and statin use were examined in the three
groups at high risk (table 2). The proportion taking
statins was 68.6% (95% CI 61.5% to 75.8%) in those with
known CVD, 57.4% (95% CI 49.1% to 65.7%) in those
with known diabetes and 19.7% (95% CI 13.0% to
26.3%) in those with a high SCORE risk (≥5%) (table 2).
A further breakdown of statin utilisation according to
prior diagnosis of angina, myocardial infarction, stroke,
TIA and revascularisation procedure is documented in
ﬁgure 2. Statin use ranged from a high of 80.3% (95%
CI 69.6% to 91.0%) in those who reported a revasculari-
sation procedure to a low of 51.6% (95% CI 32.9% to
70.2%) in those with a self-reported diagnosis of a TIA.
In individuals who reported experiencing one or more
CVD events, 78.6% (95% CI 68.1% to 89.2%) were on
statin therapy (ﬁgure 2).
Bivariate and multivariable models were used to
examine the relationship between statin utilisation and
medical card status in each of the three groups at high
risk (table 3). No association was found between
medical card status and statin utilisation in those with
known CVD or in those with known diabetes. In the
group with SCORE risk ≥5%, those with a medical card
were twice as likely to be taking statins (adjusted
RR=2.20, 95% CI 1.13 to 4.26) compared to those
without a medical card (table 3).
Lipid profiles in high-risk groups compared to guideline
targets in 2007
Over a third (38.5%, 95% CI 31.0% to 46.0%) of those
with known CVD, 46.8% (95%CI 38.4% to 55.1%) of
those with known diabetes and 85.2% (79.3%-91.1%) of
those with a SCORE risk ≥5% were at or above the
LDL-C target of 2.5 mmol/L speciﬁed in the 2007
European guidelines.12 Close to half (45.7%, 95% CI
38.1% to 53.4%) of those with known CVD, 50.3% (95%
CI 42.0% to 58.7%) of those with known diabetes and
90.8% (95% CI 86.0% to 95.6%) of those with a SCORE
risk ≥5% were at or above the total cholesterol target of
4.5 mmol/L (table 2).
Lipid profiles in high-risk groups compared to guideline
targets in 2012
The target LDL-C for those with CVD was reduced to
<1.8 mmol/L in the 2012 guidelines.3 Just over a quarter
of the CVD group (27.7%, n=46) were at the recom-
mended target LDL-C level for secondary prevention
populations using the updated guidelines published
within a year of data collection completion (not shown).
These updated guidelines recommend immediate drug
intervention at the LDL-C threshold of ≥1.8 mmol/L in
those with a very high (≥10%) SCORE risk and a thresh-
old of ≥2.5 mmol/L in those with a high (≥5% and
<10%) SCORE risk. Using these cut-off, 87% (n=123) of
those with a SCORE risk ≥5% were identiﬁed as requir-
ing immediate drug intervention based on these recent
guidelines.
Population data from Census 201118 were used to cal-
culate the absolute difference between the observed
number of high-risk individuals in the age group of
50–64 years on statin therapy and the expected number
based on the 2012 guidelines3 (table 4). In a total popu-
lation (50–64 years) of 737 694, we estimate that 51 885
individuals were on suboptimal statin treatment com-
pared to the guidelines. This includes 11 715 with
known CVD, 13 398 with known diabetes and 26 772
with a SCORE risk ≥5%.
DISCUSSION
Statement of the principal findings
The main ﬁnding in this study was that statin utilisation
for secondary prevention in those aged 50–64 years was
lower than expected based on European CVD
Table 1 Characteristics of the sample (50–64 years
TILDA wave 1)
Males
(n=1515)
Females
(n=1857)
Total
(n=3372)
Age, years 56.6 (4.2) 56.7 (4.2) 56.7 (4.2)
Education
Primary 19.1 16.1 17.5
Secondary 46.4 44.8 45.5
Tertiary 34.3 39.0 36.9
Medical card 21.6 27.1 24.6
Current smoker 18.2 18.4 18.3
Total cholesterol,
mmol/L
5.0 (0.9) 5.4 (0.9) 5.3 (1.0)
LDL-C, mmol/L 2.9 (0.9) 3.1 (0.9) 3.0 (0.9)
HDL-C, mmol/L 1.3 (0.3) 1.7 (0.4) 1.5 (0.4)
Triglycerides,
mmol/L
2.0 (1.3) 1.5 (0.9) 1.7 (1.1)
Systolic BP,
mm Hg
137.1 (17.3) 127.6 (17.9) 131.9 (18.3)
Diastolic BP,
mm Hg
85.3 (10.7) 81.4 (10.9) 83.1 (11.0)
Statins 24.0 21.2 22.5
Data are presented as mean and SD for continuous variables and
per cent for categorical variables.
BP, blood pressure; HDL-C, high-density lipoprotein cholesterol;
LDL-C, low-density lipoprotein cholesterol; TILDA, The Irish
Longitudinal Study on Ageing.
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guidelines. In those with known CVD, 68.6% were utilis-
ing statins and this ﬁgure only increased to 78.6% in
those who had experienced more than one type of CVD
event. Statin use for primary prevention in those at high
risk of CVD was also low, with 57.4% of those with
known diabetes and 19.7% of those with a SCORE risk
of ≥5% using a statin.
Secondary prevention
Despite strong evidence and clinical guidelines support-
ing the use of statins for secondary prevention in con-
junction with lifestyle interventions, a gap exists between
European CVD guidelines and clinical practice in this
cohort. Research has demonstrated poor control of risk
factors in those with coronary heart disease,19 20 despite
improvements in the use of cardioprotective medication.
The most recent EUROASPIRE IV study conducted
across 24 European countries found that statins were
used by 85.7% of patients, 6 months after an initial cor-
onary artery bypass graft, percutaneous coronary inter-
vention or acute coronary syndrome.20 Robust incentives
such as the Quality Outcomes Framework (QOF) which
rewards general practice for quality care have resulted in
an increase in statin prescription across the UK.21
Participation in the QOF is voluntary and almost all
practices take part in it. In England, the use of
lipid-lowering medication in a community cohort of
adults aged 35 years and older who self-reported ischae-
mic heart disease or stroke was 79% in men and 72% in
women in 2011.22 Recent evidence from the Action on
Secondary Prevention through Intervention to Reduce
Events (ASPIRE-2-PREVENT) survey conducted in a
stratiﬁed random sample of hospitals and general prac-
tices in the UK revealed that over 90% of those with cor-
onary heart disease were on statins.23
Previous Irish research has also demonstrated
improved statin usage in patients with established coron-
ary heart disease enrolled on Heartwatch, a programme
of secondary prevention in primary care.24 One-ﬁfth of
general practices participated in Heartwatch, inviting
their patients to attend on a quarterly basis for second-
ary prevention in addition to usual care. Statin usage
increased from 78.5% at baseline in 2003 to 89.9% in
2005 among those enrolled on the programme.25 The
current research, conducted 4 years later, shows evi-
dence of lower levels of statin utilisation and failure to
achieve guideline targets in a representative sample of
adults with known CVD living in the community. The
ﬁndings reveal that statin use among those with known
CVD was lowest in participants who had experienced a
stroke or TIA. This ﬁnding is of concern given the
strong evidence provided by the Stroke Prevention by
Aggressive Reduction in Cholesterol Levels (SPARCL)
study to support the use of high-dose statin therapy to
reduce adverse outcomes.26 The policy implications of
these ﬁndings are that secondary prevention should be
strengthened at primary care level to reduce the risk of
future CVD events in this population.
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Primary prevention
In this study, the use of statins for the primary preven-
tion of CVD was examined only in those classiﬁed as
high or very high risk (≥5%) based on SCORE. There is
ongoing debate on the beneﬁts and risks of using statins
for the primary prevention of CVD in those at low abso-
lute risk of CVD,9 27 28 and this issue is not addressed in
this paper.
In patients without established CVD but with CVD risk
factors including diabetes, statins are associated with
reductions in all-cause mortality and incidence of major
coronary and cerebrovascular events.29 Primary preven-
tion of CVD in the clinical setting requires a focus on
lifestyle modiﬁcation30 and individualised risk assess-
ment. This may take the form of a routine assessment of
a deﬁned population group similar to the Health Check
provided in the UK for all adults aged 40–74 years31 or
risk assessment on an opportunistic basis as is the
current practice in Ireland. A Cochrane review found
that general health checks did not reduce morbidity or
mortality for cardiovascular causes and insufﬁcient evi-
dence was found to support routine screening of the
population.32 Results from the recent Inter99 study
Figure 2 Proportion utilising statins by cardiovascular
disease (CVD) event type (50–64 years, The Irish
Longitudinal Study on Ageing (TILDA) wave 1).
Table 3 Risk ratio of utilising a statin for those with a
medical card in the groups at high risk of CVD
(50–64 years, TILDA wave 1)
Model 1 Model 2
RR 95% CI Adj RR 95% CI
Known CVD 0.97 0.78 to 1.19 0.91 0.72 to 1.15
Known diabetes 1.28 0.97 to 1.70 1.24 0.91 to 1.69
SCORE ≥5% 2.02* 1.04 to 3.89 2.2* 1.13 to 4.26
Model 1: unadjusted.
Model 2: adjusted for age, sex, education and frequency of GP
visits in the previous 12 months.
*p<0.05.
Adj RR, adjusted risk ratio; CVD, cardiovascular disease; GP,
general practitioner; SCORE, Systematic COronary Risk
Evaluation; TILDA, The Irish Longitudinal Study on Ageing. T
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concur, ﬁnding that an individually tailored intervention
programme with screening for risk and an individually
tailored lifestyle intervention had no effect on ischaemic
heart disease, stroke or mortality at the population level
after 10 years.33 In the absence of evidence to support
risk assessment of the entire population, opportunistic
assessment using appropriate risk assessment tools is
required to identify those at highest risk of future CVD
who may beneﬁt from primary prevention advice. The
ﬁndings of the risk assessment together with clinical
practice guidelines can be used to guide discussions
between physicians and patients with regard to the bene-
ﬁts and risks of long-term statin therapy.
Suboptimal medication
Non-adherence to prescribed medications may explain
some of the low level of statin utilisation found in our
study and the failure to achieve target levels of
LDL-C. Non-adherence to prescribed statins is known to
lead to adverse outcomes and higher costs of care.34
Adherence has been found to fall after the acute phase
following a CVD event and is low in those taking statins
for chronic coronary artery disease.35 The global
Reduction of Atherothrombosis for Continued Health
(REACH) study examined long-term adherence to medi-
cation in patients with atherothrombotic disease. The
study revealed that almost half of patients were deemed
adherent to guideline recommended medications over a
4-year period.36 Reasons for non-adherence to statins
may include statin intolerance37 and cost.38 The
reported incidence of statin intolerance is variable with
observational studies reporting muscular symptoms in
10.5% of patients on high-dose statin therapy.39 The
majority of individuals in this study with a SCORE risk
≥5% were at high risk (≥5% and <10%) as opposed to
very high risk (≥10%) of CVD mortality. It is, therefore,
possible that patient preference and willingness to
accept lifelong medication in the absence of overt
disease had a role to play in the low level of statin use in
this primary prevention group.
In our study, a quarter of the sample was eligible for a
medical card which entitled them to free GP visits and
heavily subsidised prescribed medications. The remain-
der were required to pay, out of pocket, for GP visits
(approximate cost €50–70 per visit) and prescribed medi-
cation. No evidence was found to suggest that medical
card status was associated with statin utilisation in the
groups with known CVD or diabetes. However, the posi-
tive association found between medical card status and
statin utilisation in those at high SCORE risk suggests
that ﬁnancial barriers act as a deterrent to primary pre-
vention in this high-risk group. Previous research on eli-
gibility for free GP care in Ireland has demonstrated that
those with a medical card are more likely to visit their GP
and to visit more frequently than private patients.40 In
the primary prevention context, this provides more
opportunity for those with a medical card to avail of
opportunistic risk assessment. Previous research in this
cohort has similarly demonstrated that cardiovascular
medication is utilised more frequently by those with a
medical card.41 42 The cost of statins during the study
period was high; only 8.5% of statins used by this cohort
were generic43 resulting in high cost for individuals pre-
scribed statins and without access to a medical card.
The low level (19.7%) of statin use for primary preven-
tion in those with a SCORE risk ≥5% may have resulted
from a combination of insufﬁcient risk assessment or
failure to adhere to clinical guidelines. Evidence that
guidelines are sporadically applied was demonstrated in
EUROASPIRE.44 Although physicians have been found
to support the use of guidelines and are aware of the
need to consider a combination of CVD risk factors, less
than half have been found to use guidelines or risk cal-
culators to determine total risk in European studies.45 46
Barriers to CVD guideline implementation include time
constraints;45–47 patient compliance;45 ﬁnancial limita-
tions, including lack of GP remuneration;45 46 govern-
ment health policy;45 lack of perceived usefulness,
including inadequate knowledge of the risk scoring
systems;47 and fear of over-use of medical therapies.48
Strengths and limitations of the study
The strengths of this study include the large nationally
representative sample of community-living adults which
allows us to generalise our ﬁndings to the population in
Ireland; the structured collection of interview data,
including medication data; and the use of standardised
protocols for measurements taken during the health
assessment. Non-fasting blood was analysed for lipid
levels; this may be considered a limitation. Research at
the pilot stage of TILDA found that mean total choles-
terol and LDL-C did not differ by fasting allocation49
and recent research recommends re-evaluating the rec-
ommendation that patients fast before obtaining a lipid
panel as non-fasting LDL-C has been found to have
similar prognostic value to fasting LDL-C.50
While TILDA aimed to generate a nationally represen-
tative sample, the non-response rate to the survey may
have introduced some selection bias. It is likely that
responders had a better risk factor proﬁle compared to
non-responders thus providing a more optimistic view of
risk factor management in this population. The availabil-
ity of a home and centre-based health assessment
reduced the selection bias associated with the health
assessment component of the survey.
This study is limited as it relies on self-reports of
doctors’ diagnosis of CVD and diabetes which may
underestimate the true prevalence of these conditions.
Previous research on this cohort found a lower preva-
lence of hypertension and atrial ﬁbrillation on self-
report when compared to objective measures.51 52
Markers of organ damage are not available in the
TILDA data set; some asymptomatic individuals with
organ damage may, therefore, have been misclassiﬁed to
a lower level of risk than should be the case. In this
research it is not possible to identify individuals who
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were formally risk stratiﬁed or those engaged in lifestyle
changes before consideration of pharmacological mea-
sures. Neither it is possible to identify those who discon-
tinued a statin due to intolerance nor those who
declined statin treatment following risk assessment and
consultation with their medical practitioner.
CONCLUSION
This is the ﬁrst study to examine the use of statins in
those at high risk of CVD in a nationally representative
sample of adults aged 50–64 years in Ireland. Despite
strong evidence and clinical guidelines supporting the
use of statins for secondary prevention of CVD, this study
reveals a gap between guidelines and clinical practice in
this group. An immediate policy response is required to
strengthen secondary prevention for those with existing
CVD. For the remainder of the population without evi-
dence of CVD, population strategies for primary preven-
tion are required as well as opportunistic risk assessment
to identify those at high risk of future CVD in order to
establish best practice in primary prevention.
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